These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7102092)

  • 1. [Current approaches to the development of new pharmacologically active (medicinal) substances].
    Mashkovskiĭ MD
    Vestn Akad Med Nauk SSSR; 1982; (5):9-14. PubMed ID: 7102092
    [No Abstract]   [Full Text] [Related]  

  • 2. [Problems in preclinical pharmacology when deciding on suitable animal species and animal tests models].
    Hoefke W
    Arzneimittelforschung; 1977 Feb; 27(2A):223-8. PubMed ID: 577167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proceedings of the 6th Symposium on Development and Evaluation of Pharmaceutical Preparations. Tokyo. Abstracts.
    J Pharmacobiodyn; 1986 May; 9(5):s1-21. PubMed ID: 3761132
    [No Abstract]   [Full Text] [Related]  

  • 4. [Use of cinematography in the primary evaluation of pharmacologically-active substances].
    Sardi B; Viganò V
    Boll Chim Farm; 1980 Feb; 119(2):73-7. PubMed ID: 7459031
    [No Abstract]   [Full Text] [Related]  

  • 5. Strategies for dealing with metabolite elucidation in drug discovery and development.
    Nassar AE; Talaat RE
    Drug Discov Today; 2004 Apr; 9(7):317-27. PubMed ID: 15037231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
    Whitebread S; Hamon J; Bojanic D; Urban L
    Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Responsibilities of clinical pharmacology in the early phase of drug development].
    Kuhlmann J
    Med Klin (Munich); 2000 May; 95(1 Spec No):31-40. PubMed ID: 10851846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Core trees and consensus fragment sequences for molecular representation and similarity analysis.
    Lounkine E; Bajorath J
    J Chem Inf Model; 2008 Jun; 48(6):1161-6. PubMed ID: 18491888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural product hybrids as new leads for drug discovery.
    Tietze LF; Bell HP; Chandrasekhar S
    Angew Chem Int Ed Engl; 2003 Sep; 42(34):3996-4028. PubMed ID: 12973759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery.
    Fura A; Shu YZ; Zhu M; Hanson RL; Roongta V; Humphreys WG
    J Med Chem; 2004 Aug; 47(18):4339-51. PubMed ID: 15317447
    [No Abstract]   [Full Text] [Related]  

  • 11. Predicting human pharmacokinetics from preclinical data.
    Poggesi I
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):100-11. PubMed ID: 14982153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Models for profiling the potential QT prolongation risk of drugs.
    Muzikant AL; Penland RC
    Curr Opin Drug Discov Devel; 2002 Jan; 5(1):127-35. PubMed ID: 11865666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical complementation: a definitive phenotypic strategy for identifying small molecule inhibitors of elusive cellular targets.
    Vogt A; Lazo JS
    Pharmacol Ther; 2005 Aug; 107(2):212-21. PubMed ID: 15925410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimulation software is changing research.
    Ho RL; Bartsell LT
    Biotechnol Annu Rev; 2004; 10():297-302. PubMed ID: 15504712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular diversity: from small to large, emerging to enabling.
    Hulme C; Maggiora GM
    Curr Opin Chem Biol; 2008 Jun; 12(3):257-9. PubMed ID: 18498777
    [No Abstract]   [Full Text] [Related]  

  • 16. Developing early formulations: practice and perspective.
    Li P; Zhao L
    Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety pharmacology: an essential interface of pharmacology and toxicology in the non-clinical assessment of new pharmaceuticals.
    Claude JR; Claude N
    Toxicol Lett; 2004 Jun; 151(1):25-8. PubMed ID: 15177637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of analog research in medicinal chemistry.
    Fischer J; Gere A
    Pharmazie; 2001 Sep; 56(9):675-82. PubMed ID: 11593984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unfinished business: target-based drug discovery.
    Brown D
    Drug Discov Today; 2007 Dec; 12(23-24):1007-12. PubMed ID: 18061878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.